不同剂量胸腺肽治疗慢性乙型肝炎疗效观察

目的 :探讨不同剂量胸腺肽治疗慢性乙型病毒性肝炎 (CHB)的疗效差异。方法 :14 6例CHB患者被随机分为4组 (胸腺肽 2 0 0mg组、10 0mg组、2 0mg组及对照组 )。观察 4组患者丙氨酸转移酶 (ALT)复常率、HBeAg阴转率、HBVDNA阴转率及T细胞亚群变化 ,对比并进行显著性检验处理。结果 :4组ALT复常率差异无显著性 (P >0 .0 5 )。临床疗效 (完全应答率 )胸腺肽 2 0 0mg组 (4 2 .1% )、10 0mg组 (3 4.9% )、2 0mg组 (2 6.4% )均优于对照组 (9.7% )。 2 0mg组与对照组疗效差异无显著性 (P >0 .0 5 )、10 0mg组与对照组疗效差异显著 (P <0 .0 5 )、2 0 0mg组与对照组疗效差异非常显著 (P <0 .0 1)。胸腺肽治疗各组T细胞亚群CD4升高、CD8下降、CD4/CD8比值升高且明显优于对照组 (P <0 .0 1) ,10 0mg组优于 2 0mg组 (P <0 .0 5 )。结论 :胸腺肽治疗CHB的剂量 10 0mg/d较好 ,适当增加剂量有助于提高疗效。

The Therapeutic Efficacy of Different Dose of Thymoxin for the Treatment of Chronic Hepatitis B

Objective:To evaluate the clinical implications of different doses of Thymoxine for the treatment of the patients with chronic hepatitis B. Methods:146 Chinese patients with chronic hepatitis B were divided randomly into four groups. The A group (38) was given with Thymoxine 200mg per day ; the B group (43) was given with Thymoxine 100mg per day ; the C group(34) was given with Thymoxine 20mg per day ; The control group (31) was given with the routine methods of treatment. The changes of ALT? HBeAg? HBV DNA and T cell subset in the serum were observed and analyzed.Results:There were not a significant different between four groups on the change of ALT. The entire treatment response of the A group was 42.1%?the B group was 34.9%?the C group was 26.4%?and the D group was 9.7%. The efficacy of all Thymoxine therapy group was higher than the control group, there was not a significant difference between C and D group (P>0.05), there was more significant difference between B and D group (P<0.05) and there was the most significant difference between A and D group (P<0.01). The changes of T cell subset, such as CD4?CD8?and CD4/CD8 ratio value, of all Thymoxine therapy groups was better than control group (P<0.01) and the B group was better than the C group (P<0.05).Conclusions:The better dose of Thymoxine for the treatment of the patients with chronic hepatitis B is 200mg per day.